Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study

被引：0
|
作者：
Wang, Jiabei
Peng, Tao
Liu, Chang
Zhang, Ling
Zhu, Guangzhi
Zhang, Xiaogang
Wang, Xiaoqian
Liu, Lianxin
机构：
[1] USTC, Affiliated Hosp 1, Hefei, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[4] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[5] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16239
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase II study of tislelizumab (TIS) plus sitravatinib as adjuvant therapy in patients with hepatocellular carcinoma (HCC) at high risk of recurrence after surgical resection
    Liu, L-X.
    Peng, T.
    Liu, C.
    Wang, J.
    Zhu, G.
    Zhang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1444 - S1444
  • [2] Adjuvant TACE combined with tislelizumab in patients with resected hepatocellular carcinoma at high risk of recurrence: An open-label, multicenter, phase II trial
    Ma, T.
    Wen, L.
    Zhang, J.
    Zhang, Z.
    Zeng, Y.
    Wang, Y.
    Zheng, J.
    Liang, T.
    ANNALS OF ONCOLOGY, 2024, 35 : S1494 - S1494
  • [3] Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
    Ren, Zhenggang
    Ducreux, Michel
    Abou-Alfa, Ghassan K.
    Merle, Philippe
    Fang, Weijia
    Edeline, Julien
    Li, Zhiwei
    Wu, Lihua
    Assenat, Eric
    Hu, Sheng
    Rimassa, Lorenza
    Zhang, Tao
    Blanc, Jean-Frederic
    Pan, Hongming
    Ross, Paul
    Yen, Chia-Jui
    Tran, Albert
    Shao, Guoliang
    Bouattour, Mohamed
    Chen, Yajin
    Meyer, Tim
    Hou, Jinlin
    Tougeron, David
    Bai, Yuxian
    Hou, Ming-Mo
    Meng, Zhiqiang
    Wu, John
    Li, Vincent
    Chica-Duque, Sandra
    Cheng, Ann-Lii
    LIVER CANCER, 2023, 12 (01) : 72 - 84
  • [4] Adjuvant donafenib for patients with hepatocellular carcinoma at high risk of recurrence following radical resection: A multi-center, retrospective study in China
    Zhang, ShenYu
    Yang, Guibing
    Song, Ruipeng
    Wang, Wei
    Meng, Fanzheng
    Yin, Dalong
    Wang, Jiabei
    Zhang, Shugeng
    Cai, Wei
    Liu, Yao
    Wang, Jizhou
    Luo, Dayong
    Liu, Lianxin
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [5] Sintilimab plus lenvatinib as conversion therapy in patients with unresectable hepatocellular carcinoma: A prospective, non-randomized, open-label, phase II, expansion cohort study
    Lu, S.
    Zhang, W.
    Li, J.
    Hu, B.
    Li, X.
    Liu, Z.
    Wan, T.
    Tang, H.
    Liu, B.
    Cao, Y.
    Jiao, T.
    Zhang, Z.
    Wang, Y.
    Gao, B.
    Liu, Y.
    ANNALS OF ONCOLOGY, 2023, 34 : S594 - S595
  • [6] Adjuvant lenvatinib after radical resection in patients with hepatocellular carcinoma (HCC): Preliminary analysis of a prospective, multi-center, single-arm study.
    Zhou, Jian
    Sun, Hui-Chuan
    Huang, Zhi-Yong
    Liu, Lianxin
    Wen, Tianfu
    Zhu, Xiao-Dong
    Shi, Yinghong
    Gao, Qiang
    Qiu, Shuang-Jian
    Ding, Zhenbin
    Wang, Zheng
    Ye, Qing-Hai
    Huang, Xiao-Wu
    Huang, Cheng
    Peng, Yuan-Fei
    Shi, Guoming
    Wang, Xiao-Ying
    Fan, Jia
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16) : E16158 - E16158
  • [7] A multi-center, open-label, non-randomized phase II study of elsamitrucin (SPI-28090) in patients with relapsed or refractory non-hodgkin's lymphoma (NHL).
    Mohrbacher, A
    Sanani, S
    Irwin, D
    Espina, BM
    Madrid, C
    Lenaz, L
    Rosales, R
    BLOOD, 2004, 104 (11) : 232B - 232B
  • [8] A phase 2, multicenter study to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in patients with HCC at high risk of recurrence after curative resection
    Liang, Tingbo
    Zhang, Zongli
    Zheng, Jinfang
    Wang, Yijun
    Zhang, Jialin
    Li, Bo
    Ma, Tao
    Xu, Yunfei
    Wu, Changxiong
    Sun, Quan
    Meng, Yiman
    Yang, Xiaoli
    CANCER RESEARCH, 2022, 82 (12)
  • [9] An open-label, multi-center phase IIIb study of durvalumab and tremelimumab as first-line treatment in patients with unresectable hepatocellular carcinoma (TREMENDOUS study).
    Fan, Jia
    Qin, Shukui
    Sun, Hui-Chuan
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : TPS628 - TPS628
  • [10] Updated results of the PATH study: Adjuvant therapy with donafenib plus a PD-1 inhibitor for patients with hepatocellular carcinoma at high risk of recurrence after resection
    Chen, Yiwen
    Shen, Yan
    Zhang, Min
    Wu, Jian
    Gao, Shunliang
    Que, Risheng
    Yu, Jun
    Tang, Xiaofeng
    Bai, Xueli
    Liang, Tingbo
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 571 - 571
12345